Dyne Therapeutics, Inc. (DYN)
- Previous Close
26.00 - Open
26.31 - Bid 26.60 x 200
- Ask 26.75 x 100
- Day's Range
26.25 - 28.00 - 52 Week Range
6.40 - 30.27 - Volume
953,084 - Avg. Volume
1,245,300 - Market Cap (intraday)
2.326B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-3.98 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.22
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
www.dyne-tx.comRecent News: DYN
Performance Overview: DYN
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DYN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DYN
Valuation Measures
Market Cap
2.27B
Enterprise Value
1.85B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.75
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.98%
Return on Equity (ttm)
-71.50%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-257.4M
Diluted EPS (ttm)
-3.98
Balance Sheet and Cash Flow
Total Cash (mrq)
453.55M
Total Debt/Equity (mrq)
5.57%
Levered Free Cash Flow (ttm)
-152.87M
Research Analysis: DYN
Company Insights: DYN
DYN does not have Company Insights